PMID- 23114786
OWN - NLM
STAT- MEDLINE
DCOM- 20140818
LR  - 20220311
IS  - 1437-7772 (Electronic)
IS  - 1341-9625 (Linking)
VI  - 18
IP  - 6
DP  - 2013 Dec
TI  - Efficacy and safety of temsirolimus in Japanese patients with metastatic renal 
      cell carcinoma on hemodialysis.
PG  - 1054-9
LID - 10.1007/s10147-012-0492-7 [doi]
AB  - BACKGROUND: We retrospectively investigated the efficacy and safety of 
      temsirolimus, an inhibitor of the mammalian target of rapamycin, in patients with 
      metastatic renal cell carcinoma (mRCC) on hemodialysis (HD). METHODS: This study 
      included ten HD patients who were diagnosed with mRCC following radical 
      nephrectomy and subsequently treated with temsirolimus between December 2010 and 
      June 2012. Medical records of these patients were reviewed to evaluate the 
      response to temsirolimus and treatment-related toxicities. RESULTS: Baseline 
      characteristics of the patients are as follows: median age was 61 years, five 
      patients had a Karnofsky performance status of </=80, and two, six, and two 
      patients were classified into favorable, intermediate, and poor risk group, 
      respectively, according to the Memorial Sloan-Kettering Cancer Center risk model. 
      Initially, all patients received 25 mg intravenous temsirolimus weekly; however, 
      dose modification was necessary in four patients, resulting in a relative dose 
      intensity of 89.5 % throughout this study. All patients, except for one with 
      progressive disease, were judged to have stable disease following treatment with 
      temsirolimus. Six patients are still under treatment with temsirolimus, whereas 
      four have stopped receiving temsirolimus because of the occurrence of progressive 
      disease in three and that of adverse events (AEs) in one. Although all patients 
      experienced AEs related to temsirolimus, severe AEs corresponding to >/= grade 3 
      occurred in only four, including thrombocytopenia in two, anemia in one, and 
      asthenia in one. CONCLUSIONS: Treatment with temsirolimus is well tolerated and 
      could provide comparatively favorable cancer control in Japanese mRCC patients 
      undergoing HD.
FAU - Miyake, Hideaki
AU  - Miyake H
AD  - Division of Urology, Kobe University Graduate School of Medicine, 7-5-1 
      Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan, hideakimiyake@hotmail.com.
FAU - Harada, Ken-Ichi
AU  - Harada K
FAU - Kusuda, Yuji
AU  - Kusuda Y
FAU - Fujisawa, Masato
AU  - Fujisawa M
LA  - eng
PT  - Journal Article
DEP - 20121101
PL  - Japan
TA  - Int J Clin Oncol
JT  - International journal of clinical oncology
JID - 9616295
RN  - 624KN6GM2T (temsirolimus)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse 
      effects
MH  - Carcinoma, Renal Cell/*drug therapy/pathology
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis/drug therapy/pathology
MH  - Renal Dialysis
MH  - Retrospective Studies
MH  - Sirolimus/administration & dosage/adverse effects/*analogs & derivatives
EDAT- 2012/11/02 06:00
MHDA- 2014/08/19 06:00
CRDT- 2012/11/02 06:00
PHST- 2012/08/25 00:00 [received]
PHST- 2012/10/14 00:00 [accepted]
PHST- 2012/11/02 06:00 [entrez]
PHST- 2012/11/02 06:00 [pubmed]
PHST- 2014/08/19 06:00 [medline]
AID - 10.1007/s10147-012-0492-7 [doi]
PST - ppublish
SO  - Int J Clin Oncol. 2013 Dec;18(6):1054-9. doi: 10.1007/s10147-012-0492-7. Epub 
      2012 Nov 1.